Combination of anlotinib and albumin-bound paclitaxel in 2<sup>nd</sup> line and above treatment of advanced gastric cancer: A retrospective study
The combination of anlotinib and nab-ptx shows promising efficacy with fewer toxicities in AGC treatment. The regimen holds promise as a second-line treatment of AGC; however, its specific clinical value requires further research.
Authors
- Yi Peng (ORCID: https://orcid.org/0000-0002-5319-1336)
- Y. Liu (ORCID: https://orcid.org/0009-0002-6495-6004)
- Jing Tang (ORCID: https://orcid.org/0000-0003-1013-147X)
- Wenming Liu (ORCID: https://orcid.org/0000-0002-7044-1130)
- Xiaobing Li (ORCID: https://orcid.org/0000-0001-9105-6365)
Institutions
- The First People's Hospital of Tianmen (CN)
- Hubei Cancer Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- World Journal of Clinical Oncology
- Published
- 2025-03-26
- DOI
- https://doi.org/10.5306/wjco.v16.i4.102199
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00